Some molecular markers, such as IDH, 1p/19q codeletion, EGFR amplification, CDKN2A/B loss, and TERT promoter mutation, etc. have been routinely tested in clinical practice and cooperated with histopathological information to form the classification scheme of glioma (49). This evidence concerns the gene TERT and glioma.